Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors

Lung cancer patients undergoing systemic treatment with immune checkpoint inhibitors (ICIs) can lead to severe immune-related adverse events (irAEs) that may warrant immediate hospitalization. Patients with thoracic malignancies hospitalized at City of Hope while undergoing treatment with ICIs were...

Full description

Bibliographic Details
Main Authors: Dan Zhao, Haiqing Li, Isa Mambetsariev, Chen Chen, Rebecca Pharaon, Jeremy Fricke, Angel R. Baroz, Prakash Kulkarni, Yan Xing, Erminia Massarelli, Marianna Koczywas, Karen L. Reckamp, Kim Margolin, Ravi Salgia
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
lung cancer
checkpoint inhibitors
immune-related adverse events (irAEs)
admissions
genomic alterations
next-generation sequencing
Online Access:https://www.mdpi.com/2072-6694/13/11/2653

Internet

https://www.mdpi.com/2072-6694/13/11/2653

Similar Items